DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Authors: Dr Samir Seleq, PGY2 House Officer, Auckland Public Hospital, New Zealand; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand; June 2015.
DermNet NZ Update May 2021. Copy edited by Gus Mitchell.
Sézary syndrome is a rare leukaemic variant of cutaneous T-cell lymphoma (CTCL) defined by the triad of erythroderma, lymphadenopathy, and atypical malignant Sézary cells in the skin, blood, and lymph nodes.
Erythroderma of Sézary syndrome
Sézary syndrome typically presents in patients 55–60 years of age, with a male predominance (2:1). The annual incidence is estimated to be 1/10,000, with a higher incidence in black skin over white. Sézary syndrome comprises 3% of all cases of CTCL.
Sézary syndrome arises from a skin tropic memory CD41 T-cell. The role of Staphylococcus aureus superantigen or chronic antigen stimulation has been proposed to lead to clonal expansion of T-cell and malignant transformation.
Sézary cells show diverse and complex chromosomal anomalies affecting many cellular pathways. Many genetic alterations have been identified in recent large-scale surveys, providing information on the molecular pathogenesis and offering new therapeutic targets under investigation.
A viral aetiology has not been identified.
Cutaneous features of Sézary syndrome
Sézary syndrome presents at a younger age in black patients than white (53 v 63 years of age) and survival is worse regardless of age and stage at diagnosis.
Sézary syndrome should be considered in the differential diagnosis for any patient presenting with erythroderma.
Imaging may include: chest x-ray, lymph node field ultrasound, CT, MRI, PET.
Staging for MF/SS: TNMB (tumour, node, metastasis, blood) – Sézary syndrome must, by definition, be T4 – erythroderma, N0-3, B2 – Sezary cells >1000/mm3 in peripheral blood, M0-1.
Poor prognostic factors for Sézary syndrome:
The median survival of Sézary syndrome is estimated to be 3–5 years with a five-year survival of less than 30%.
Books about skin diseases
© 2022 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.